DR. LAL PATH LABS LTD. (LALPATHLAB) financials

DR. LAL PATH LABS LTD. (LALPATHLAB) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The se…

Market Cap: ₹31,218Cr.
Current Price: ₹1,860
Stock P/E: 55.2
ROE: 22.9%
ROCE: 28.5%
Book Value: ₹148
Dividend Yield: 0.75%
52W High / Low: ₹2,039/1,272

In Jun 2026, DR. LAL PATH LABS LTD. (LALPATHLAB) reported sales ₹764 Cr and net profit ₹166 Cr.

Annual TTM: sales ₹2,771 Cr, net profit ₹545 Cr.

Shareholding: Promoters 52.93% (Sep 2026), FIIs 18.73% (Sep 2026), DIIs 21.57% (Sep 2026), Government 0.00% (Sep 2026), Public 6.35% (Sep 2026).

LALPATHLAB quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	631	569	577	641	700	632	675	764
Expenses	437	418	418	457	484	458	494	526
Operating Profit	194	151	159	183	215	174	182	238
OPM %	31%	27%	28%	29%	31%	27%	27%	31%
Other Income	24	31	25	26	23	-4	37	30
Interest	6	5	5	4	5	7	6	6
Depreciation	33	34	35	33	38	40	43	40
Profit before tax	179	144	145	172	195	123	170	222
Tax %	28%	27%	-2%	25%	25%	25%	17%	25%
Net Profit	129	105	148	129	146	92	141	166
EPS in Rs	7.71	6.30	8.88	7.71	8.69	5.50	8.42	9.90
Raw PDF	—	—	—	—	—	—	—	—

LALPATHLAB profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	1,274	1,491	1,879	1,769	2,125	2,352	2,648	2,771
Expenses	946	1,083	1,366	1,308	1,544	1,684	1,893	1,962
Operating Profit	328	408	512	461	581	668	755	809
OPM %	26%	27%	27%	26%	27%	28%	29%	29%
Other Income	58	51	53	47	66	109	82	86
Interest	15	15	29	34	29	22	22	24
Depreciation	68	70	76	82	136	134	154	161
Profit before tax	303	374	461	391	483	621	660	710
Tax %	26%	25%	25%	25%	28%	20%	23%	—
Net Profit	223	280	345	292	347	497	508	545
EPS in Rs	13.39	16.80	20.71	17.54	20.76	29.74	30.33	32.51
Dividend Payout %	45%	60%	29%	34%	43%	40%	68%	—

LALPATHLAB balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	83	83	83	83	83	83	84	168
Reserves	847	933	1,134	1,389	1,606	1,717	2,051	2,305
Borrowings	0	0	0	385	281	142	151	193
Other Liabilities	136	302	356	354	350	406	336	383
Total Liabilities	1,067	1,318	1,573	2,211	2,320	2,349	2,621	3,049
Fixed Assets	173	297	300	371	361	1,104	1,051	1,143
CWIP	3	11	9	14	5	6	3	7
Investments	214	253	171	1,062	1,213	213	416	513
Other Assets	677	757	1,093	764	740	1,026	1,151	1,386
Total Assets	1,067	1,318	1,573	2,211	2,320	2,349	2,621	3,049

LALPATHLAB cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	208	272	373	426	428	478	540	606
Cash from Investing Activity	-93	-19	-195	-449	-288	32	-293	-382
Cash from Financing Activity	-54	-187	-136	141	-270	-404	-325	-256
Net Cash Flow	61	65	42	118	-131	106	-78	-32
Free Cash Flow	170	224	338	358	390	429	488	436
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	110%	110%	115%	106%	114%	104%	104%	102%

LALPATHLAB shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	53.91%	53.91%	53.79%	53.21%	53.21%	53.21%	53.19%	52.93%
FIIs	26.82%	23.90%	21.69%	21.86%	20.29%	17.18%	17.35%	18.73%
DIIs	12.88%	15.79%	17.62%	18.22%	19.20%	21.37%	21.59%	21.57%
Government	0.29%	0.29%	0.29%	0.27%	0.01%	0.01%	0.01%	0.00%
Public	5.82%	5.84%	6.22%	6.07%	6.94%	7.88%	7.48%	6.35%
Others	0.28%	0.27%	0.39%	0.37%	0.35%	0.34%	0.38%	0.41%
No. of Shareholders	1,16,236	1,15,699	1,18,656	1,12,703	1,16,167	1,14,527	1,11,037	1,13,559

LALPATHLAB key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	17	14	16	13	13	15	16	18
Inventory Days	40	70	38	32	22	28	26	29
Days Payable	110	143	132	101	131	154	130	126
Cash Conversion Cycle	-54	-59	-79	-55	-96	-111	-88	-79
Working Capital Days	1	-16	-25	-57	-61	-46	-28	-25
ROCE %	34%	33%	35%	32%	22%	26%	30%	29%

LALPATHLABUpdated 19 Oct 2026, 5:44

Dr. Lal Path Labs Ltd.

LALPATHLABUpdated 19 Oct 2026, 5:44

Market Cap

₹31,218Cr.

Current Price

₹1,860

High / Low

₹2,039/1,272

Stock P/E

55.2

ROE22.9%

ROCE28.5%

Book Value₹148

Face Value₹10.0

Dividend Yield0.75%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	480	7	344	15	18	125	25	94	5.61
Sep 2023	532	7	369	14	19	151	25	113	6.77
Dec 2023	476	6	346	15	19	120	26	88	5.29
Mar 2024	521	6	383	16	35	113	29	81	4.84
Jun 2024	574	6	413	31	33	154	26	114	6.86
Sep 2024	631	6	437	24	33	179	28	129	7.71
Dec 2024	569	5	418	31	34	144	27	105	6.3
Mar 2025	577	5	418	25	35	145	-2	148	8.88
Jun 2025	641	4	457	26	33	172	25	129	7.71
Sep 2025	700	5	484	23	38	195	25	146	8.69
Dec 2025	632	7	458	-4	40	123	25	92	5.5
Mar 2026	675	6	494	37	43	170	17	141	8.42
Jun 2026	764	6	526	30	40	222	25	166	9.9

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	637	0	486	17	32	135	32	92	8.4
Mar 2016	765	0	562	20	32	192	34	126	7.6
Mar 2017	882	1	651	28	26	231	34	152	9.18
Mar 2018	1024	1	768	31	31	256	34	168	10.09
Mar 2019	1165	1	882	46	36	292	33	195	11.72
Mar 2020	1274	15	946	58	68	303	26	223	13.39
Mar 2021	1491	15	1083	51	70	374	25	280	16.8
Mar 2022	1879	29	1366	53	76	461	25	345	20.71
Mar 2023	1769	34	1308	47	82	391	25	292	17.54
Mar 2024	2125	29	1544	66	136	483	28	347	20.76
Mar 2025	2352	22	1684	109	134	621	20	497	29.74
Mar 2026	2648	22	1893	82	154	660	23	508	30.33
TTM	2771	24	1962	86	161	710	—	545	32.51

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	52.93%
FIIs	18.73%
DIIs	21.57%
Public	6.35%
Others	0.41%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public	Others
Dec 2023	54.6%	25.36%	9.27%	0.29%	10.12%	0.37%
Mar 2024	54.6%	26.15%	9.4%	0.29%	9.24%	0.32%
Jun 2024	54.6%	25.43%	12.42%	0.29%	6.95%	0.3%
Sep 2024	53.92%	26.82%	12.6%	0.29%	6.02%	0.33%
Dec 2024	53.91%	26.82%	12.88%	0.29%	5.82%	0.28%
Mar 2025	53.91%	23.9%	15.79%	0.29%	5.84%	0.27%
Jun 2025	53.79%	21.69%	17.62%	0.29%	6.22%	0.39%
Sep 2025	53.21%	21.86%	18.22%	0.27%	6.07%	0.37%
Dec 2025	53.21%	20.29%	19.2%	0.01%	6.94%	0.35%
Mar 2026	53.21%	17.18%	21.37%	0.01%	7.88%	0.34%
Jun 2026	53.19%	17.35%	21.59%	0.01%	7.48%	0.38%
Sep 2026	52.93%	18.73%	21.57%	0%	6.35%	0.41%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	55	238	27	130	449	119	1	49	280	449
Mar 2016	83	397	0	112	592	130	4	74	384	592
Mar 2017	83	503	0	90	676	121	17	134	404	676
Mar 2018	83	693	0	119	896	173	9	174	540	896
Mar 2019	83	847	0	136	1067	173	3	214	677	1067
Mar 2020	83	933	0	302	1318	297	11	253	757	1318
Mar 2021	83	1134	0	356	1573	300	9	171	1093	1573
Mar 2022	83	1389	385	354	2211	371	14	1062	764	2211
Mar 2023	83	1606	281	350	2320	361	5	1213	740	2320
Mar 2024	83	1717	142	406	2349	1104	6	213	1026	2349
Mar 2025	84	2051	151	336	2621	1051	3	416	1151	2621
Mar 2026	168	2305	193	383	3049	1143	7	513	1386	3049

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	94	-86	1	9
Mar 2016	142	-148	1	-5
Mar 2017	167	-134	-32	1
Mar 2018	189	-166	13	36
Mar 2019	208	-93	-54	61
Mar 2020	272	-19	-187	65
Mar 2021	373	-195	-136	42
Mar 2022	426	-449	141	118
Mar 2023	428	-288	-270	-131
Mar 2024	478	32	-404	106
Mar 2025	540	-293	-325	-78
Mar 2026	606	-382	-256	-32

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	17	17	17	14	17	14	16	13	13	15	16	18
Inventory Days	37	31	33	44	40	70	38	32	22	28	26	29
Days Payable	89	88	97	104	110	143	132	101	131	154	130	126
Cash Conversion Cycle	-35	-41	-47	-45	-54	-59	-79	-55	-96	-111	-88	-79
Working Capital Days	-10	28	15	18	1	-16	-25	-57	-61	-46	-28	-25
ROCE %	51%	48%	44%	38%	34%	33%	35%	32%	22%	26%	30%	29%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of DR. LAL PATH LABS LTD. (LALPATHLAB)?

The reported market capitalisation for DR. LAL PATH LABS LTD. (LALPATHLAB) is ₹31,218Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of LALPATHLAB?

The current price shown for DR. LAL PATH LABS LTD. (LALPATHLAB) on Fincrux is ₹1,860 with a 52-week high/low of ₹2,039/1,272.

What is the P/E ratio of DR. LAL PATH LABS LTD. (LALPATHLAB)?

The stock P/E for DR. LAL PATH LABS LTD. (LALPATHLAB) is 55.2 on Fincrux, with ROE at 22.9% and ROCE at 28.5%.

What were LALPATHLAB latest quarterly results?

For Jun 2026, DR. LAL PATH LABS LTD. (LALPATHLAB) reported sales ₹764 Cr and net profit ₹166 Cr (figures in ₹ crore unless noted).

What are LALPATHLAB annual sales and net profit?

For TTM, DR. LAL PATH LABS LTD. (LALPATHLAB) shows sales of ₹2,771 Cr and net profit of ₹545 Cr on the Fincrux profit & loss statement.

Who owns DR. LAL PATH LABS LTD. (LALPATHLAB)?

Latest shareholding for DR. LAL PATH LABS LTD. (LALPATHLAB) on Fincrux: Promoters 52.93% (Sep 2026), FIIs 18.73% (Sep 2026), DIIs 21.57% (Sep 2026), Government 0.00% (Sep 2026), Public 6.35% (Sep 2026).

Where can I find DR. LAL PATH LABS LTD. (LALPATHLAB) financials?

DR. LAL PATH LABS LTD. (LALPATHLAB) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show LALPATHLAB balance sheet and cash flow?

Yes. The DR. LAL PATH LABS LTD. (LALPATHLAB) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 5:44